Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

JDRF calls for AstraZeneca to explain type 1 diabetes drug withdrawal

JDRF is calling for AstraZeneca to clearly explain to people with type 1 diabetes why a drug licenced for the treatment of adults with the condition has been withdrawn.
Breakthrough T1D profile picture
Kate Gerrard 16 November 2021

A smartly-dressed woman having a discussion with a man.

AstraZeneca last week alerted clinicians that the drug dapagliflozin, also known by its brand name Forxiga, would be withdrawn immediately for type 1 diabetes use in the UK and EU.

The decision could affect up to 2,000 people in the UK with type 1 diabetes, even though, according to AstraZeneca, there are no new safety issues with the drug.

Clear explanation for withdrawal needed

JDRF is now calling on AstraZeneca to clearly explain to people affected by type 1 diabetes why the drug has been withdrawn for use treating that condition. The drug will continue to be available for other conditions including type 2 diabetes.

Dapagliflozin is a once-a-day pill which, when used alongside standard insulin therapy, significantly improves blood glucose management for many people with the life-threatening condition.

The first of its kind to be approved in the UK and EU for adults with type 1 diabetes, it is the only other drug besides insulin that has been licensed in the UK to treat type 1 diabetes.

Huge advancement in type 1 treatment

Its development was one of the biggest advancements in the treatment of type 1 diabetes since the discovery of insulin 100 years ago.

JDRF has long advocated for therapies that can improve the lives of those affected by type 1 diabetes, including treatments such as dapagliflozin. It was made available on the NHS as an ‘adjunct therapy’ to be used alongside insulin for people with type 1 diabetes by NICE in July 2019.

Managing type 1 diabetes with insulin alone is challenging and intensive, leaving a significant physical and mental burden upon the individual. Currently, just 30 per cent of people with type 1 diabetes reach their recommended blood glucose targets, putting them at greater risk of health complications.

Lower HbA1c levels

Dapagliflozin helps to reduce blood glucose levels by stopping the kidneys from reabsorbing glucose into the body. Instead, excess glucose is passed out in urine. Previous clinical trials showed that, when used alongside insulin, the drug helped people lower their HbA1c levels (a measure of average blood glucose levels) without increasing the incidence of hypoglycaemic events. Keeping HbA1c levels as close to the recommended target of 6.5% as possible is important in preventing long-term type 1 diabetes complications.

Karen Addington, UK Chief Executive of JDRF, said: “Dapagliflozin has been the first drug offered in 100 years since the discovery of insulin that has helped people with type 1 diabetes to manage their condition. It is appalling that it is now being withdrawn, even though many people with type 1 are finding it an effective and useful tool to help manage their glucose levels. Breakthrough T1D UK asks AstraZeneca to explain to people in the UK affected by type 1 diabetes the reasons behind this withdrawal.”

Anyone affected by the withdrawal of dapagliflozin should contact their healthcare professional.

Related news

Read more
Mum and daughter wearing Breakthrough T1D t-shirts and holding a flag in a park.
News
16 December 2024

Research and policy breakthroughs in 2024

Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.

Read more
A photograph of two women. The woman on the right is a healthcare professional who has a hand on the other woman's arm.
Research
12 November 2024

New policy framework launches to improve sex and gender data in UK research

The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.

Read more
A young woman wearing a continuous glucose monitor looks on to a man scanning his sensor.
News
29 October 2024

New report calls for more equal access to type 1 diabetes technology

Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.

Read more
A researcher sits in a lab beside screening samples and lab equipment for early detection of type 1 diabetes.
Research
24 June 2024

New guidance sets out how to support people with early-stage type 1 diabetes

New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.